CliffBio
small molecule

TYLENOL WITH NAPROXEN

ACETAMINOPHEN; NAPROXEN SODIUM

Loss of exclusivityJuly 2029FDA regulatory exclusivity expiry
CompanyKENVUE BRANDS LLC

Drug detail

Brand nameTYLENOL WITH NAPROXEN
Active ingredientACETAMINOPHEN; NAPROXEN SODIUM
Strength325MG;110MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJuly 2026
Marketing statusOTC

Regulatory exclusivity

CodeExpires
NPJuly 2029

More from KENVUE BRANDS LLC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.